Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 8:13:569-580.
doi: 10.2147/DDDT.S147499. eCollection 2019.

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Robert Ali  1 , Junaid Arshad  1 , Sofia Palacio  1 , Raja Mudad  2
Affiliations
Review

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Robert Ali et al. Drug Des Devel Ther. .

Abstract

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Keywords: ALK inhibitors; ALK positive; TKI; brigatinib; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Raja Mudad has attended one advisory board for brigatinib by Takeda Pharmaceuticals, and received an honorarium for that activity in March 2018. The authors report no other conflicts of interest in this work.

References

    1. SEER . Cancer stat facts: lung and bronchus cancer. Bethesda, MD: National Cancer Institute; [Accessed January 21, 2019]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html.
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med Overseas Ed. 2002;346(2):92–98. - PubMed
    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. - PubMed
    1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. - PMC - PubMed
    1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer Who Harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. - PMC - PubMed

MeSH terms